New shot for obesity shows promise in early trial
NCT ID NCT06679959
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new injectable drug called ASC30 in 115 adults with obesity. The goal was to check its safety, how the body processes it, and its effect on weight. Participants received either the drug or a placebo, and researchers monitored side effects and weight changes over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ASC30 injection
- What this could lead to
- If successful, this could lead to a new injectable medication for weight management in people with obesity.
- What could go wrong
- This is an early-phase trial (phase I/IIa) with only 115 participants, so results may not apply broadly. Safety and effectiveness are still being tested, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC WEIGHT MANAGEMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ascletis clinical site
San Antonio, Texas, 78209, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?